The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).
 
Amy Jo Chien
Research Funding - Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst)
 
Siti Rahmaputri
No Relationships to Disclose
 
Heidi F Dittrich
No Relationships to Disclose
 
Melanie Catherine Majure
No Relationships to Disclose
 
Hope S. Rugo
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech (I); Pfizer (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Galena Biopharma (Inst); Genentech (Inst); Lilly (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Andrei Goga
No Relationships to Disclose